BioAdaptives Acquisition Target Xycota Biosciences Launches Free PTSD Tactical & Support Hub for Veterans and First Responders Alongside At-Home Psilocybin Research
Preferred stock and convertible notes under the acquisition agreement will dilute existing BioAdaptives stockholders.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioAdaptives (BDPT) and pending acquisition target Xycota Biosciences highlighted the launch of Xycota's free PTSD support hub for veterans and first responders. The hub requires no registration, collects no cloud personal health data and is separate from trial recruitment.
BioAdaptives signed a definitive acquisition agreement on October 29, 2026; the transaction has not closed. Terms include milestone-gated research funding, a 12-month founder lock-up and daily selling caps on financing notes. A proposed nutraceutical spin-off has conditional funding; preferred stock and convertible notes will dilute existing holders.
Xycota's XYCO-02 is designed for potential at-home use. A 2026 study found low-dose psilocybin restored recognition memory in rats modeling Fragile X syndrome, not PTSD. Neither XYCO-02 nor XYCO-01 has entered a company-sponsored human study; no trial is recruiting.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointDefinitive agreement signed October 29, 2026 to acquire preclinical biotechnology company Xycota Biosciences.
- Minor pointFounder lock-up lasts 12 months under the acquisition agreement.
- Minor pointFinancing notes carry contractual daily selling caps.
- Minor point. Forward-looking: it has not happened yet and may not happen.Proposed nutraceutical spin-off could ultimately give eligible stockholders shares in two separate companies.
- Minor pointLow-dose psilocybin restored object-recognition memory in a rat model of Fragile X syndrome, not PTSD.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Preferred stock and convertible notes issuance and conversion under the agreement will dilute existing stockholders.
- Minor pointXycota acquisition remains pending and has not closed.
- Minor point. Forward-looking: it has not happened yet and may not happen.Research funding is subject to milestone-gated tranches.
- Minor point. Forward-looking: it has not happened yet and may not happen.Proposed nutraceutical spin-off funding remains conditional.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LAS VEGAS, NV AND SHERIDAN, WY / ACCESS Newswire / November 11, 2026 / Recognizing Veterans Day week, BioAdaptives, Inc. (OTCID:BDPT) and its pending acquisition target Xycota Biosciences, LLC today highlighted the public launch of Xycota's free PTSD Community & Resource Hub (https://xycota.com/ptsd), a zero-login digital support and grounding resource built for veterans, active-duty service members, first responders, and caregivers.
Guided by decorated 37-year U.S. Marine Corps Reserve and U.S. Army Reserve combat veteran Lt. Col. Elton Johnson Jr. (Ret.), an incoming Xycota board designee, alongside Xycota Co-Founder and Chief Scientific Officer Marvin S. Hausman, M.D. (a former U.S. Public Health Service Surgeon at the National Institutes of Health), the hub provides practical, zero-cost tools that require no registration and collect no cloud personal health data:
- Immediate Nervous-System Grounding Tools: Interactive 60-second physiological sigh pacer, 4-4-4-4 box breathing timer, and 5-4-3-2-1 sensory reset for acute stress spikes.
- Confidential Vetted Resource Matcher: Direct connections to established, zero-cost support organizations including VA Vet Centers, The Headstrong Project, Cohen Veterans Network, Warrior Care Network / Home Base, Team Rubicon, and Copline (for law enforcement), plus immediate 988 Veterans Crisis Line access.
- Private On-Device Log and Family Field Guides: A local browser-only sleep and calm tracker exportable for a personal physician, paired with shareable guides helping spouses and families understand trauma physiology.
The hub is strictly educational and supportive, does not provide medical advice, and is completely separate from clinical-trial recruitment or enrollment.
Why Real-World Access Drives Xycota's Sub-Perceptual Psilocybin Research
The same real-world barrier shapes Xycota's pharmaceutical research: working veterans, first responders, and parents rarely have six to eight hours to spend inside a clinic for a hallucinogenic therapy session. Xycota's lead investigational candidate, XYCO-02, is a low-dose oral psilocybin capsule designed for potential at-home use below the threshold of noticeable psychedelic effects, targeting the BDNF/TrkB synaptic repair pathway.
In a 2026 Neuropsychopharmacology study (Ascone et al.) co-authored by Dr. Hausman, repeated low-dose oral psilocybin restored object-recognition memory in a genetic rat model of Fragile X syndrome; the benefit held when hallucination-linked serotonin receptors were blocked and vanished when TrkB was blocked. That study was conducted strictly in rats, did not evaluate PTSD, and has not been tested in humans. Updated investor and scientific briefings, including Xycota's follow-on exosome-formulated psilocin program for frontotemporal dementia (XYCO-01), are available at https://xycota.com/investors.
"Before our drug candidates ever reach a human trial, we wanted to put free, private, zero-red-tape tools directly into the hands of veterans, first responders, and their families today," said Brad Listermann, Co-Founder and Chief Executive Officer of Xycota Biosciences. "On the corporate side, we built our agreement with BioAdaptives around the same long-term discipline: milestone-gated R&D tranches, a 12-month founder lock-up, contractual daily selling caps on financing notes, and conditional funding for a proposed nutraceutical spin-off designed so eligible stockholders could ultimately own shares in two separate companies."
"Chronic trauma leaves a measurable physical imprint on synaptic connections, not a character flaw," said Marvin S. Hausman, M.D., Co-Founder and Chief Scientific Officer of Xycota Biosciences. "Pairing immediate, accessible community education with a rigorous clinical test of whether sub-perceptual psilocybin can engage BDNF/TrkB repair signaling without hallucinations reflects who we are as a company."
About BioAdaptives and Xycota Biosciences
BioAdaptives, Inc. (OTCID:BDPT) markets human and animal dietary supplements and signed a definitive agreement on October 29, 2026 to acquire preclinical CNS biotechnology company Xycota Biosciences, LLC. The transaction has not closed and remains subject to closing conditions detailed in the Form 8-K filed November 4, 2026 (https://www.sec.gov/Archives/edgar/data/1575142/000164033426001712/bdpt_8k.htm).
Regulatory and Forward-Looking Disclosures
XYCO-01 and XYCO-02 are preclinical, investigational candidates involving Schedule I controlled substances; neither has been tested in a company-sponsored human study or approved by the FDA, Health Canada, or any regulator, and no safety or efficacy claims are made. No clinical trial is currently recruiting. BioAdaptives' dietary supplements are unrelated to Xycota's pharmaceutical programs and are not intended to diagnose, treat, cure, or prevent any disease.
This release contains forward-looking statements regarding pending acquisition closing, milestone financing, a proposed spin-off, potential stockholder distributions, and planned research. Actual results may differ materially. Closing, funding, regulatory clearances, and any spin-off depend on conditions that may not be satisfied. Animal findings may not translate to humans or PTSD. Issuance and conversion of preferred stock and convertible notes under the agreement will dilute existing BioAdaptives stockholders. Review BioAdaptives' November 4, 2026 Form 8-K and other SEC filings. Not an offer to sell or solicitation to buy any security.
Contacts BioAdaptives, Inc.:
Drew@BioAdaptives.com | (702) 659-8829 | X: @BioAdaptivesInc
Xycota Biosciences: Brad Listermann | brad@xycota.com
Brad Listermann - CEO
Xycota Biosciences, LLC
xycota.com
SOURCE: BioAdaptives, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.